Inclusion Criteria:

- Confirmed diagnosis of mantle cell lymphoma (MCL)

- Received at least 1 prior rituximab-containing chemotherapy regimen (separate lines
of therapy are defined as single or combination therapies that are either separated
by disease progression or by a > 6 month treatment-free interval)

- Documented relapse or disease progression following the last anti-MCL treatment

- At least 1 measurable site of disease according to Revised Response Criteria for
Malignant Lymphoma

- Eastern Cooperative Oncology Group performance status grade 0 or 1

- Protocol-defined hematology and biochemistry laboratory values

Exclusion Criteria:

- Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic
anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10
weeks, radiation therapy or other investigational agents within 3 weeks, or major
surgery within 4 weeks of randomization

- Prior treatment with temsirolimus, other mTOR inhibitors, ibrutinib, or other
Bruton's tyrosine kinase (BTK) inhibitors

- Known central nervous system lymphoma

- Received an allogeneic or autologous hematopoietic stem cell transplant <=6 months
from the date of randomization and on immunosuppressive therapy or have evidence of
active graft versus host disease

- Diagnosed or treated for malignancy other than MCL, except: malignancy treated with
curative intent and with no known active disease present for >=3 years before
randomization, adequately treated non-melanoma skin cancer or lentigo maligna without
evidence of disease, adequately treated cervical carcinoma in situ without evidence
of disease

- History of stroke or intracranial hemorrhage within 6 months prior to randomization

- Requires anticoagulation with warfarin or equivalent vitamin K antagonist

- Requires treatment with strong CYP3A4/5 inhibitor

- Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined
by the New York Heart Association Functional Classification

- Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV)
or active hepatitis B virus (HBV) infection or any uncontrolled active systemic
infection requiring intravenous antibiotics

- Woman who is pregnant or breast-feeding

- Any life-threatening illness, medical condition, or organ system dysfunction which,
in the investigator's opinion, could compromise the patient's safety, interfere with
the absorption or metabolism of ibrutinib capsules, or put the study outcomes at
undue risk